Humacyte (HUMA) Retained Earnings (2020 - 2026)
Humacyte (HUMA) posted quarterly Retained Earnings of $756.1 million for Q1 2026, up 10.71% year-over-year from $682.9 million in Q1 2025, and up 204.02% quarter-over-quarter from -$726.8 million in Q4 2025.
Humacyte (HUMA) Retained Earnings (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Retained Earnings for 7 consecutive years, with $756.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 10.71% year-over-year to $756.1 million; the TTM figure through Mar 2026 stood at $756.1 million (up 10.71% YoY), while the FY2025 annual figure was -$726.8 million, down 5.95% from the prior year.
- Retained Earnings improved to $756.1 million in Q1 2026 per HUMA's latest filing, from -$726.8 million in the prior quarter.
- Across five years, Retained Earnings topped out at $756.1 million in Q1 2026 and bottomed at -$726.8 million in Q4 2025.
- Historically, Retained Earnings has averaged -$271.5 million across 5 years, with a median of -$463.5 million in 2023.
- Annual changes were most pronounced in 2022 — Retained Earnings plunged 5319.3% — and 2023, when it surged 229.89%.
- Humacyte's Retained Earnings stood at -$426.5 million in 2022, then declined by 25.98% to -$537.3 million in 2023, then fell by 27.67% to -$686.0 million in 2024, then fell by 5.95% to -$726.8 million in 2025, then soared by 204.02% to $756.1 million in 2026.
- Business Quant data shows HUMA's Retained Earnings at $756.1 million in Q1 2026, -$726.8 million in Q4 2025, and -$702.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 4.38 Bn |
| 10 | Humacyte | 154.65 Mn | 154.65 Mn | -825,000.00 | 812.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 812.50 Mn |
| Mar 31, 2026 | 756.07 Mn |
| Dec 31, 2025 | -726.85 Mn |
| Sep 30, 2025 | -702.04 Mn |
| Jun 30, 2025 | -684.50 Mn |
| Mar 31, 2025 | 682.90 Mn |
| Dec 31, 2024 | -686.02 Mn |
| Sep 30, 2024 | -665.10 Mn |
| Jun 30, 2024 | 597.57 Mn |
| Mar 31, 2024 | -569.20 Mn |
| Dec 31, 2023 | -537.31 Mn |
| Sep 30, 2023 | 549.19 Mn |
| Jun 30, 2023 | -486.21 Mn |
| Mar 31, 2023 | -463.51 Mn |
| Dec 31, 2022 | -426.50 Mn |
| Sep 30, 2022 | -422.82 Mn |
| Jun 30, 2022 | -397.54 Mn |
| Mar 31, 2022 | -434.41 Mn |
| Dec 31, 2021 | -414.57 Mn |
| Sep 30, 2021 | -457.20 Mn |